Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ocular Therapeut (OCUL)

Ocular Therapeut (OCUL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,358,430
  • Shares Outstanding, K 213,047
  • Annual Sales, $ 63,720 K
  • Annual Income, $ -193,510 K
  • EBIT $ -251 M
  • EBITDA $ -247 M
  • 60-Month Beta 0.93
  • Price/Sales 34.50
  • Price/Cash Flow N/A
  • Price/Book 7.20

Options Overview Details

View History
  • Implied Volatility 304.08% (+34.68%)
  • Historical Volatility 88.09%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 304.08% on 01/14/26
  • IV Low 46.01% on 08/22/25
  • Expected Move (DTE 1) 1.32 (11.90%)
  • Put/Call Vol Ratio 0.43
  • Today's Volume 16,483
  • Volume Avg (30-Day) 4,928
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 129,586
  • Open Int (30-Day) 95,643
  • Expected Range 9.75 to 12.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.33
  • Number of Estimates 5
  • High Estimate -0.31
  • Low Estimate -0.36
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -13.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.96 +11.14%
on 01/14/26
14.85 -25.47%
on 12/15/25
-3.49 (-23.97%)
since 12/12/25
3-Month
9.96 +11.14%
on 01/14/26
16.44 -32.66%
on 12/08/25
-0.16 (-1.42%)
since 10/14/25
52-Week
5.78 +91.36%
on 03/04/25
16.44 -32.66%
on 12/08/25
+3.21 (+40.84%)
since 01/14/25

Most Recent Stories

More News
3 Reasons OCUL is Risky and 1 Stock to Buy Instead

3 Reasons OCUL is Risky and 1 Stock to Buy Instead

OCUL : 11.07 (+6.14%)
1 Unprofitable Stock with Impressive Fundamentals and 2 We Find Risky

1 Unprofitable Stock with Impressive Fundamentals and 2 We Find Risky

AXON : 629.22 (-1.92%)
XRX : 2.50 (+1.63%)
OCUL : 11.07 (+6.14%)
3 Stocks Under $50 with Questionable Fundamentals

3 Stocks Under $50 with Questionable Fundamentals

TGNA : 18.91 (-0.21%)
ACHC : 11.73 (-6.53%)
OCUL : 11.07 (+6.14%)
3 of Wall Street’s Favorite Stocks Walking a Fine Line

3 of Wall Street’s Favorite Stocks Walking a Fine Line

TMHC : 63.47 (-2.73%)
SCSC : 41.26 (-0.48%)
OCUL : 11.07 (+6.14%)
Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales

Ocular Therapeutix (NASDAQ:OCUL) Surprises With Q3 CY2025 Sales

OCUL : 11.07 (+6.14%)
Ocular Therapeutix™ Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI™ in Wet AMD

Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage...

OCUL : 11.07 (+6.14%)
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...

OCUL : 11.07 (+6.14%)
Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDR

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global,...

OCUL : 11.07 (+6.14%)
Ocular Therapeutix™ to Participate in November and December Investor Conferences

BEDFORD, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...

OCUL : 11.07 (+6.14%)
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BEDFORD, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced...

OCUL : 11.07 (+6.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular...

See More

Key Turning Points

3rd Resistance Point 12.65
2nd Resistance Point 11.89
1st Resistance Point 11.48
Last Price 11.07
1st Support Level 10.31
2nd Support Level 9.55
3rd Support Level 9.14

See More

52-Week High 16.44
Fibonacci 61.8% 12.37
Fibonacci 50% 11.11
Last Price 11.07
Fibonacci 38.2% 9.86
52-Week Low 5.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar